Search bioRxiv⌕ Search

bioRxiv · 10.1101/2024.11.18.624143

Challenges and promises in optimising a non-clinical protocol of intracerebroventricular human neural stem cell transplantation in ALS

Abstract

Background and aimsNeural stem cell (NSC) transplantation holds promising therapeutic potential for neurodegenerative disorders like amyotrophic lateral sclerosis (ALS). However, pre-clinical studies and early-phase clinical trials have faced challenges hindering the effective clinical translation of this approach. Crucial hurdles include the side-effects of prolonged immunosuppression, concerns regarding cell origin and transplantation dosage, identification of the most appropriate therapeutic window, and invasiveness of surgical procedures. Here, we show challenges and promises in optimizing a non-clinical protocol to assess safety and efficacy of human NSC (hNSC) intracerebroventricular (ICV) transplantation for ALS. MethodsWe evaluated the safety of administering up to 1x106 hNSCs in immunodeficient mice and assessed their potential efficacy in reducing ALS hallmarks employing the SOD1G93A mouse model. Both, transient (15 days) and prolonged immunosuppression regimens, at low (15 mg/kg) and high (30 mg/kg) doses, were tested along with two different cell dosages (3x105 and 1x106). ResultsBilateral ICV injection of up to 1x106 hNSCs proved to be safe, with no evidence of tumor formation. At 40 days post-transplantation, hNSCs induced a trend toward delaying motor decline and reducing spinal cord (SC) microgliosis when transplanted under prolonged high-dose (30 mg/kg) immunosuppression. ConclusionsOur study suggests that: (i) a bilateral ICV transplantation of 1x106 hNSCs is safe and non-tumorigenic in immunodeficient hosts; (ii) sustained high-dose immunosuppression is essential for ensuring cell survival in immunocompetent mice; and (iii) hNSC transplantation may provide therapeutic benefits in ALS by delaying motor decline and reducing microgliosis. This study also highlights persisting hurdles that need to be further addressed, such as the aggressive murine immune response to exogenous cells.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Lombardi, I., Ferrero, C., Vulcano, E., Rasa', D. M., Gelati, M., Campos, D. P., Carletti, R. M., De La Morena, S., Profico, D. C., Longobardi, S., Lazzarino, E., Perciballi, E., Rosati, J., Perez, S. M., Vercelli, A., Boido, M. M., Ferrari, D.. 2024-11-19. Challenges and promises in optimising a non-clinical protocol of intracerebroventricular human neural stem cell transplantation in ALS. https://doi.org/10.1101/2024.11.18.624143

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

E2F4 gene therapy reverses established synaptic and cognitive deficits and remodels learning-associated signaling in Alzheimer's disease mice

Alzheimer's disease (AD) causes progressive synaptic dysfunction, neurodegeneration, and cognitive decline, yet strategies capable of reversing established deficits remain limited. Here, we show that neuronal expression of a p38MAPK phosphorylation-resistant human E2F4 variant (hE2F4DN), delivered by adeno-associated virus, restores hippocampal long-term potentiation and memory in homozygous 5xFAD mice after functional impairment is established. Treatment also reduces amyloid-{beta} and phospho-tau pathology and prevents hippocampal neuronal loss. Integrated proteomic and phosphoproteomic analyses reveal remodeling of metabolic, redox, neuroimmune, synaptic-vesicle, and GSK3{beta}-associated signaling pathways. Following contextual fear conditioning, hE2F4DN-treated mice exhibit broader learning-associated synaptic proteomic signatures and distinct phosphoregulatory responses involving synaptic machinery. These findings demonstrate that E2F4 gene therapy can reverse established synaptic and cognitive deficits while preserving neuronal integrity and reshaping molecular responses to learning, identifying E2F4 phosphorylation as a potential therapeutic target for advanced AD states.

neuroscience↗

Complex Spatial and Temporal Organization of Functional Brain Networks

Recent research exploring brain-behavior associations has relied on the language of complex systems to understand how stable behavioral individual differences emerge from brain function. At the same time, advances in neuroimaging have provided greater insight into both the topological and temporal properties of macroscale cortical networks. These new approaches offer a potential avenue for understanding how functional activity in the brain might behave in a manner that aligns with complex-systems interpretations of psychological traits. The present study used resting-state data from the Human Connectome project (N = 994) to explore associations between the spatial and temporal features of functional brain networks. Using an adaptive frequency approach to explore brain function at different timescales together with a family of methods from complex systems theory, we identified patterns of brain state organization reflecting a state-trait continuum, with more stable trait-like dynamics and greater functional coupling between networks in lower frequency oscillations. Additionally, we found evidence of greater coupling across timescales in brain networks associated with higher-order cognition. This research supports interpretations of brain organization as a spatiotemporal hierarchy and provides future avenues for exploring brain-behavior associations from a complex system perspective.

neuroscience↗

A Mechanistic Account of Dedifferentiation in the Aging Visual System

To uncover the mechanisms of age-related dedifferentiation, we simulated neural degradation in a computational model of the ventral visual stream. Severing connections or adding noise, whether in inferotemporal cortex (IT) or upstream, reduced IT differentiation, indicating that dedifferentiation need not originate locally. Degrading peripheral V1, which preferentially drove place-selective IT neurons, selectively reduced place differentiation, a candidate mechanism for the stronger place dedifferentiation reported in aging.

neuroscience↗